基本信息
浏览量:344
职业迁徙
个人简介
Born and educated in Germany, Dr Meenhard Herlyn received his D.V.M. at the University of Veterinary Medicine, Hanover in 1970 and went on to receive a D.Sc. in medical microbiology at the University of Munich in 1976. Dr Herlyn came to The Wistar Institute as an associate scientist in 1976, where he worked in the emerging field of monoclonal antibodies; a technology that formed the basis of much of today's new targeted therapeutics. In 1981, Dr Herlyn became an assistant professor and established a laboratory that is, today, one the largest and most celebrated research groups on the study of melanoma biology.
Dr Herlyn's laboratory at The Wistar Institute focuses on the biology that underlies melanoma, the most aggressive form of skin cancer. His efforts have pioneered the use of the three-dimensional "artificial skin" tumour cultures to study the behaviour of both tumours and the other cells that sustain tumour growth, a system known as the tumour microenvironment. The Herlyn laboratory has transformed the scientific understanding of stem cells as they relate to cancer, and their work on the networks of signaling pathways in melanoma has formed the basis of numerous therapies now in development or currently under clinical trial.
The ability to model the microenvironment of normal and diseased human tissue through 3-D artificial skin provides the Herlyn laboratory with a unique insight into cancer research. Growing cells in these tissue-like models induces major changes in gene expression similar to those in animals and patients, making them superbly suited for studies of signaling between cells, tumor formation, and drug resistance. These models also make a unique testing ground for ideas on future therapeutics or drug combinations.
The Herlyn laboratory also seeks to further define the various signaling pathways that work in cancer cells in order to discover new opportunities to inhibit cancer growth through targeted therapeutics. Since therapy is increasingly guided by the genetic aberrations in tumours, Dr Herlyn and his colleagues are developing combinations of compounds that take into account the genetic signature of tumours, with the long-term goal of individualized cancer therapy. Currently, the Herlyn laboratory collaborates with pharmaceutical companies as well as academic chemists and structural biologists to select and further develop compounds for tumour inhibition.
Another major effort of the Herlyn laboratory is the study of therapeutic resistance and tumour dormancy. Tumour cells can become dormant in primary tumours or at any time after metastatic dissemination and can persist in the dormant state for many years, allowing tumours to resist treatment. Dr Herlyn's working hypothesis is that defined tumour subpopulations are central to dormancy and drug resistance due to their slow turnover and their non-responsiveness to growth signals. His efforts seek to define how tumour cells escape dormancy for growth, invasion, and metastasis, and how to best develop strategies for therapy.
研究兴趣
论文共 275 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Kasturee Jagirdar,Marie E. Portuallo,Meihan Wei, Matthew Wilhide,Jeremy A. Bravo Narula, Bailey M. Robertson,Gretchen M. Alicea, Crystal Aguh, Min Xiao,Tetiana Godok,Dylan Fingerman,Gregory Schuyler Brown,
Research squareno. 6 (2024): 395-405
bioRxiv (Cold Spring Harbor Laboratory) (2023)
引用0浏览0引用
0
0
Jill C. Rubinstein, Sergii Domanskyi,Todd Sheridan, Brian J. Sanderson, Sung-Hee Park, Jessica Kaster,Haiyin Li, Olga Anczuków,Meenhard Herlyn, Jeffrey H. Chuang
Cancer Researchno. 7_Supplement (2023): 1164-1164
引用0浏览0引用
0
0
biorxiv(2021)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn